Abstract
Hepatocellular Carcinoma (HCC) is the most prevalent liver malignancy. Trans arterial chemoembolization (TACE) is the gold standard treatment for Barcelona Clinic Liver Cancer (BCLC) stage B patients, who are considered to have unresectable HCC. In the following review it is shown that BCLC stage B group is too heterogenous, at the same time some patient may present a better outcome by receiving a more aggressive procedure, while others may benefit from systemic therapy. Those methods suggest which is the optimal treatment for BCLC stage B patients and when to apply it. Apart from alternatives to TACE, this review has highlighted other situations when TACE may be used – BCLC stage A or C.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: BULLETIN OF THE TRANSILVANIA UNIVERSITY OF BRASOV SERIES VI - MEDICAL SCIENCES
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
